Primer Examines TPP’s Potential Impact On Drugs’ Data Exclusivity

Brookings Institution’s “Health360”: Health Policy 101: How the Trans-Pacific Partnership Will Impact Prescription Drugs
This primer discusses biologic and biosimilar drugs and concerns over “the length of data exclusivity granted to the companies that hold the patents on these drugs” contained in the Trans-Pacific Partnership (TPP), a free trade agreement that the U.S. has been negotiating with 11 other countries (5/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.